Elevated levels of fructosamine are independently associated with SARS-CoV-2 reinfection: A 12-mo follow-up study

doi:10.4239/wjd.v13.i7.543

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 7

This Article

(193)

(186)

(0)

(13)

(2)

(4697)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Observational Study

World J Diabetes. Jul 15, 2022; 13(7): 543-552
Published online Jul 15, 2022. doi: 10.4239/wjd.v13.i7.543

Full Size Figure Download Figure

Figure 3 Potential pathways for reinfection in patients with high fructosamine levels and increased angiotensin-converting enzyme 2 expression. FMN: Fructosamine; ACE2: Angiotensin-converting enzyme 2; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2.

Citation: Huang XY, Yang LJ, Hu X, Zhang XX, Gu X, Du LJ, He ZY, Gu XJ. Elevated levels of fructosamine are independently associated with SARS-CoV-2 reinfection: A 12-mo follow-up study. World J Diabetes 2022; 13(7): 543-552
URL: https://www.wjgnet.com/1948-9358/full/v13/i7/543.htm
DOI: https://dx.doi.org/10.4239/wjd.v13.i7.543

Huang XY, Yang LJ, Hu X, Zhang XX, Gu X, Du LJ, He ZY, Gu XJ. Elevated levels of fructosamine are independently associated with SARS-CoV-2 reinfection: A 12-mo follow-up study. World J Diabetes 2022; 13(7): 543-552 [PMID: 36051424 DOI: 10.4239/wjd.v13.i7.543]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.